Comment on: A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis

被引：0

作者：

Sato, Takeo ^{[1
]}

Inokuma, Shigeko ^{[1
]}

机构：

[1] Japanese Red Cross Med Ctr, Dept Allerg Dis & Rheumatol, Shibuya Ku, Tokyo 1508935, Japan

来源：

RHEUMATOLOGY | 2010年 / 49卷 / 08期

关键词：

D O I：

10.1093/rheumatology/keq106

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1607 / 1607

页数：1

共 50 条

[21] Mycophenolate mofetil (CellCept®) for psoriasis:: A two-center, prospective, open-label clinical trial
Zhou, YW
Rosenthal, D
Dutz, J
Ho, V
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2003, 7 (03) : 193 - 197
[22] AN OPEN-LABEL STUDY OF AMBRISENTAN WITH ANTI-FIBROTIC AGENT COMBINATION THERAPY IN THE TREATMENT OF DIFFUSE SYSTEMIC SCLEROSIS
Schorpion, A.
Shenin, M.
Neubauer, R.
Derk, C. T.
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 896 - 896
[23] Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis
Le, Elizabeth N.
Wigley, Fredrick M.
Shah, Ami A.
Boin, Francesco
Hummers, Laura K.
ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (06) : 1104 - 1107
[24] Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial
Jessica K. Gordon
Viktor Martyanov
Cynthia Magro
Horatio F. Wildman
Tammara A. Wood
Wei-Ti Huang
Mary K. Crow
Michael L. Whitfield
Robert F. Spiera
Arthritis Research & Therapy, 17
[25] Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial
Gordon, Jessica K.
Martyanov, Viktor
Magro, Cynthia
Wildman, Horatio F.
Wood, Tammara A.
Huang, Wei-Ti
Crow, Mary K.
Whitfield, Michael L.
Spiera, Robert F.
ARTHRITIS RESEARCH & THERAPY, 2015, 17
[26] A prospective, open-label, non-comparative study of ambrisentan with anti-fibrotic agent combination therapy in the treatment of diffuse systemic sclerosis
Schorpion A.
Shenin M.
Neubauer R.
Derk C.T.
BMC Rheumatology, 2 (1)
[27] SIMVASTATIN IN SYSTEMIC SCLEROSIS PATIENTS - AN OPEN-LABEL STUDY
Ionitescu, S. C.
Mihai, C.
Bojinca, M.
Sfrent-Cornateanu, R.
Ion, A.
Macovei, L.
Manea, O.
Sasu, M.
Ancuta, I.
Milicescu, M.
Mogosan, C.
Abobului, M.
Berghea, F.
Predeteanu, D.
Ionescu, R.
Stoica, V.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S158 - S158
[28] Enteric-coated mycophenolate sodium for progressive systemic sclerosis—a prospective open-label study with CT histography for monitoring of pulmonary fibrosis
Joerg C. Henes
Marius Horger
Christopher Amberger
Marc Schmalzing
Gerhard Fierlbeck
Lothar Kanz
Ina Koetter
Clinical Rheumatology, 2013, 32 : 673 - 678
[29] Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial
Chakravarty, Eliza F.
Utset, Tammy
Kamen, Diane L.
Contreras, Gabriel
McCune, W. Joseph
Aranow, Cynthia
Kalunian, Kenneth
Massarotti, Elena
Clowse, Megan E. B.
Rovin, Brad H.
Lim, S. Sam
Majithia, Vikas
Dall'Era, Maria
Looney, R. John
Erkan, Doruk
Saxena, Amit
Olsen, Nancy J.
Ko, Kichul
Guthridge, Joel M.
Goldmuntz, Ellen
Springer, Jessica
D'Aveta, Carla
Keyes-Elstein, Lynette
Barry, Bill
Pinckney, Ashley
Mcnamara, James
James, Judith A.
LANCET RHEUMATOLOGY, 2024, 6 (03): : e168 - e177
[30] Stabilization of Microcirculation in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement following Rituximab Treatment: An Open-label Study
Smith, Vanessa
Pizzorni, Carmen
Riccieri, Valeria
Decuman, Saskia
Brusselle, Guy
De Pauw, Michel
Deschepper, Ellen
Piette, Yves
Ruaro, Barbara
Sulli, Alberto
Vandecasteele, Els
Melsens, Karin
De Keyser, Filip
Cutolo, Maurizio
JOURNAL OF RHEUMATOLOGY, 2016, 43 (05) : 995 - 996

← 1 2 3 4 5 →